


# **AMENDMENTS TO THE CLAIMS**

Please amend claims 1-26, 30, 32 and 33 and add new claim 34. Please cancel claims 27-29 without prejudice or disclaimer. Deletions appear in ~~striketrough font~~, and additions are underlined. This listing of claims below will replace all prior versions and listings of claims in the application.

## **Complete listing of claims**

1. (Currently amended) A compound of formula (I):



wherein

B ~~is~~represents a group chosen from a phenyl, naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, ~~or~~biphenyl group, or ~~and~~a 5 to 10-membered heteroaromatic group containing one or more heteroatoms selected ~~chosen~~from N, O or ~~and~~S;

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent a group chosen from a hydrogen atom, ~~or~~a halogen atom, ~~or~~a hydroxy, phenyl, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>6</sup>, -NHCOR<sup>5</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -CN, -NO<sub>2</sub>, -COOR<sup>5</sup>, ~~or~~-CF<sub>3</sub> group, or ~~a straight~~optionally substituted lower alkyl group, or ~~and~~a branched, optionally substituted lower alkyl group;

or R<sup>1</sup> and R<sup>2</sup> together form an aromatic or alicyclic ring or a heterocyclic group;

$R^5$  and  $R^6$  each independently represent a group chosen from a hydrogen atom, a straight optionally substituted lower alkyl group ~~or and~~ a branched, optionally substituted lower alkyl group, or  $R^5$  and  $R^6$  together form an alicyclic ring;

$n$  is an integer from 0 to 4;


$A$  represents a group chosen selected from  $-\text{CH}_2-$ ,  $-\text{CH}=\text{CR}^7-$ ,  $-\text{CR}^7=\text{CH}-$ ,  $-\text{CR}^7\text{R}^8-$ ,  $-\text{CO}-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ ,  $-\text{S}(\text{O})_2-$  and  $-\text{NR}^7-$ , wherein  $R^7$  and  $R^8$  each independently represent a group chosen from hydrogen atom, a straight optionally substituted lower alkyl group ~~or and~~ a branched, optionally substituted lower alkyl group, or  $R^7$  and  $R^8$  together form an alicyclic ring;

$m$  is an integer from 0 to 8;


$R^4$  represents a lower alkyl group;

$D$  represents a group of formula i) or ii)

i)



ii)



wherein

$R^9$  represents a group chosen selected from phenyl, 2-furyl, 3-furyl, 2-thienyl ~~or and~~ 3-thienyl;

$R^{10}$  represents a group chosen selected from phenyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl ~~or and~~  $\text{C}_3\text{-C}_7$  cycloalkyl;

and R<sup>11</sup> represents a group chosen from a hydrogen atom, or a hydroxy, methyl, or and CH<sub>2</sub>OH group;

wherein each of the cyclic groups represented by R<sup>9</sup> and R<sup>10</sup> being is independently optionally substituted by one or two substituents chosen selected from halogen, straight optionally substituted lower alkyl, or branched, optionally substituted lower alkyl, hydroxy, optionally substituted lower alkoxy, nitro, cyano, -CO<sub>2</sub>R<sup>12</sup> or and -NR<sup>12</sup>R<sup>13</sup>, wherein R<sup>12</sup> and R<sup>13</sup> are identical or different and are each independently chosen selected from a hydrogen atom, and straight optionally substituted lower alkyl groups or and branched, optionally substituted lower alkyl groups;

Q represents a single bond or a group chosen from -CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -O-, -O-CH<sub>2</sub>-, -S-, -S-CH<sub>2</sub>- or and -CH=CH-group;

X<sup>-</sup> represents a pharmaceutically acceptable anion of a mono or polyvalent acid;

including all or an individual stereoisomers of a compound of formula (I) or and a mixtures of stereoisomers of a compound of formula (I) thereof;

with the proviso that in those compounds of formula (I) wherein B is phenyl, R<sup>9</sup> is unsubstituted phenyl, R<sup>10</sup> is unsubstituted phenyl or unsubstituted C<sub>3</sub>-C<sub>7</sub> cycloalkyl, and R<sup>11</sup> is hydrogen or hydroxy, the sequence - (CH<sub>2</sub>)<sub>n</sub> - A - (CH<sub>2</sub>)<sub>m</sub> - is not one of methylene, ethylene or propylene.

2. (Currently amended) A compound according to claim 1, wherein B represents a group chosen from phenyl, pyrrolyl, thienyl, furyl, biphenyl, naphthalenyl, 5, 6, 7,

- 8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, imidazolyl ~~or and~~ benzothiazolyl-group.
3. (Currently amended) A compound according to claim 2, wherein B represents a group chosen from phenyl, thienyl or and pyrrolyl-group.
  4. (Currently amended) A compound according to claim 1, any one of the preceding claims wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represents a group chosen from a hydrogen atom, or a halogen atom, or a hydroxy, methyl, tert-butyl, -CH<sub>2</sub>OH, 3-hydroxypropyl, -OMe, -NMe<sub>2</sub>, -NHCOMe, -CONH<sub>2</sub>, -CN, -NO<sub>2</sub>, -COOMe or and -CF<sub>3</sub>-group.
  5. (Currently amended) A compound according to claim 4, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represents a group chosen from hydrogen, fluorine, chlorine or and hydroxy.
  6. (Currently amended) A compound according to claim 1, any one of the preceding claims wherein n = 0 or 1; m is an integer from 1 to 6; and A represents a group chosen from -CH<sub>2</sub>-, -CH=CH-, -CO-, -NMe-, -O- or and -S- group.
  7. (Currently amended) A compound according to claim 6, wherein A is a group chosen from -CH<sub>2</sub>-, -CH=CH- or and -O-group.
  8. (Currently amended) A compound according to claim 6, wherein the pyrrolidinium group is substituted on the nitrogen atom with a C<sub>1</sub>-C<sub>4</sub> alkyl group and another group chosen selected from 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 3-(3-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 3-thien-2-ylpropyl, 4-oxo-4-thien-2-ylbutyl, 2-benzyloxyethyl, 3-o-tolyloxypropyl, 3-(3-cyanophenoxy)propyl, 3-(methylphenylamino)propyl, 3-phenylsulphanylpropyl, 4-oxo-4-phenylbutyl, 4-(4-

fluorophenyl)-4-oxobutyl, 3-(2-chlorophenoxy)propyl, 3-(2,4-difluorophenoxy)propyl, 3-(4-methoxyphenoxy)propyl, and 3-(benzo[1,3]dioxol-5-yloxy)propyl.

9. (Currently amended) A compound according to claim 8 wherein the pyrrolidinium group is substituted on the nitrogen atom with a C<sub>1</sub>-C<sub>4</sub> alkyl group and another group chosen ~~selected~~ from 3-phenoxypropyl, 2-phenoxyethyl, 3-phenylallyl, phenethyl, 3-phenylpropyl, 3-(3-hydroxyphenoxy)propyl, 3-(4-fluorophenoxy)propyl, 4-(4-fluorophenyl)-4-oxobutyl ~~or~~ and 3-thien-2-ylpropyl.
10. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein D is a group of formula i), and wherein R<sup>9</sup> is a group chosen ~~selected~~ from phenyl, 2-thienyl ~~or~~ and 2-furyl; R<sup>10</sup> is a group chosen ~~selected~~ from phenyl, 2-thienyl, cyclohexyl ~~or~~ and cyclopentyl; and R<sup>11</sup> is a hydroxy group.
11. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 9~~ wherein D is a group of formula ii), and wherein Q is a single bond or an oxygen atom and R<sup>11</sup> is a hydrogen atom or a hydroxy group.
12. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein X<sup>-</sup> is chosen from chloride, bromide, trifluoroacetate ~~or~~ and methanesulphonate.
13. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims~~ wherein the carbon at the 3-position of the pyrrolidinium ring has a R configuration.
14. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 12~~ wherein the carbon at the 3-position of the pyrrolidinium ring has a S configuration.

15. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 10 and 12 to 14~~ wherein D is a group of formula i) and the carbon substituted by R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> has a R configuration.
16. (Currently amended) A compound according to claim 1, ~~any one of claims 1 to 10 and 12 to 14~~ wherein D is a group of formula i) and the carbon substituted by R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> has a S configuration.
17. (Currently amended) A compound according to claim 1, ~~any one of the preceding claims, which wherein said compound~~ is a single isomer.
18. (Currently amended) A compound according to claim 1 ~~which is one of~~ chosen from:
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium trifluoroacetate;
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-thien-2-ylpropyl)pyrrolidinium bromide;
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl) pyrrolidinium bromide;
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(-3-phenylallyl)pyrrolidinium trifluoroacetate;
  - 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(4-oxo-4-thien-2-ylbutyl)pyrrolidinium trifluoroacetate;
  - 1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium trifluoroacetate;
  - 1-Ethyl-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]pyrrolidinium trifluoroacetate;

3-(2-Hydroxy-2,2-dithien-2-yl-acetoxy)-1-methyl-1-(3-pyrrol-1-ylpropyl)pyrrolidinium trifluoroacetate;  
 3-(2-Hydroxy-2,2-dithien-2-ylacetoxo)-1-methyl-1-[6-(4-phenylbutoxy)hexyl]pyrrolidinium trifluoroacetate;  
 1-(2-Benzoyloxyethyl)-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;  
 1-[3-(3-Cyanophenoxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;  
 3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(naphthalen-1-yloxy)propyl]pyrrolidinium trifluoroacetate;  
 3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(methylphenylamino)propyl]pyrrolidinium trifluoroacetate;  
 3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-ethyl-1-(3-phenylsulphanylpropyl)pyrrolidinium trifluoroacetate;  
 1-[3-(Benzothiazol-2-yloxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium trifluoroacetate;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(2,4,6-trimethylphenoxy)propyl]pyrrolidinium trifluoroacetate;  
 1-[3-(2-Chlorophenoxy)propyl]-3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methylpyrrolidinium trifluoroacetate;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(3-trifluoromethylphenoxy)propyl]pyrrolidinium trifluoroacetate;  
 1-[3-(Biphenyl-4-yloxy)propyl]-3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methylpyrrolidinium trifluoroacetate;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-[3-(2,4-difluorophenoxy)propyl]-1-methylpyrrolidinium trifluoroacetate;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-ethyl-1-[3-(4-methoxyphenoxy)propyl]-pyrrolidinium trifluoroacetate;

3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium trifluoroacetate;  
 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1-methyl-1-[3-(1-methyl-1H-imidazol-2-ylsulphanyl)propyl]pyrrolidinium trifluoroacetate;  
 1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;  
 1-Methyl-1-(3-phenoxypropyl)-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;  
 1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-[3-(2-Carbamoylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-[3-(3-Dimethylaminophenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-[3-(4-Acetylaminophenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-[3-(4-Methoxycarbonylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-Methyl-1-[3-(4-nitrophenoxy)propyl]-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 1-[3-(4-Hydroxymethylphenoxy)propyl]-1-methyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium trifluoroacetate;  
 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]-1-methylpyrrolidinium formate;  
 1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium chloride;  
 3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenylpropyl)pyrrolidinium bromide;  
 1-Methyl-1-(3-o-tolyloxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide;



3-[[[(9-hydroxy-9H-fluoren-9-yl)carbonyl]oxy]-1-methyl-1-(4-oxo-4-phenylbutyl)pyrrolidinium formate; and

3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-ethyl-1-(3-phenylsulfonylpropyl)pyrrolidinium bromide.

19. (Currently amended) A compound according to claim 1 ~~which is one of~~ chosen from:

(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide;

(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-phenethylpyrrolidinium bromide;

(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;

(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide;

(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-thien-2-ylpropyl)pyrrolidinium bromide;

(3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3R)-3-[(2R)-2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy]-1-ethyl-1-(3-phenylsulphonylpropyl)pyrrolidinium trifluoroacetate;

(3S)-3-[(2R)-2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy]-1-ethyl-1-(3-phenylsulphonylpropyl)pyrrolidinium trifluoroacetate;

(3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;

(3R)-3-[(2S)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;  
 (3S)-3-[(2S)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide;  
 (3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;  
 (3S)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium bromide;  
 (3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-[3-(3-hydroxyphenoxy)propyl]-1-methylpyrrolidinium formate;  
 (3R)-3-[[9-hydroxy-9H-fluoren-9-yl]carbonyl]oxy)-1-methyl-1-(4-oxo-4-phenylbutyl)pyrrolidinium formate;  
 (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(4-oxo-4-thien-2-ylbutyl)pyrrolidinium chloride;  
 (3R)-1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-methylpyrrolidinium formate;  
 (3R)-1-[3-(3-Cyanophenoxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium formate;  
 (3R)-3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(naphthalen-1-yloxy)propyl]pyrrolidinium formate;  
 (3R)-3-(2-Cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methyl-1-[3-(methylphenylamino)propyl]pyrrolidinium chloride;  
 (3R)-1-[3-(Benzothiazol-2-yloxy)propyl]-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxy)-1-methylpyrrolidinium chloride;  
 (3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride;  
 (3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide;  
 (3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(1-methyl-1H-imidazol-2-ylsulfanyl)propyl]pyrrolidinium chloride;

(3R)-1-[3-(2-Chlorophenoxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxyl]-1-methylpyrrolidinium chloride;  
 3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxyl]-1-ethyl-1-[3-(4-methoxyphenoxy)propyl]pyrrolidinium bromide; and  
 (3R)-1-(2-Benzyloxyethyl)-3-(2-cyclohexyl-2-fur-2-yl-2-hydroxyacetoxyl)-1-methylpyrrolidinium bromide.

20. (Currently amended) A compound according to claim 1 ~~which is one of~~ chosen from:
- (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-phenethylpyrrolidinium bromide (diastereomer 1);
  - (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-phenethylpyrrolidinium bromide (diastereomer 2);
  - (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 1);
  - (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 2);
  - (1\*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 1);
  - (1\*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(2-phenoxyethyl)pyrrolidinium bromide (diastereomer 2);
  - (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 1);
  - (1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxyl)-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 2);
  - (1\*, 3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxyl]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 1);
  - (1\*, 3S)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxyl]-1-methyl-1-(3-phenoxypropyl)pyrrolidinium bromide (diastereomer 2);

(1\*,3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium  
bromide (diastereomer 1);

(1\*,3R)-1-Methyl-1-phenethyl-3-(9H-xanthen-9-ylcarbonyloxy)pyrrolidinium  
bromide (diastereomer 2);

(1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-  
phenylallyl)pyrrolidinium bromide (diastereomer 1);

(1\*, 3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-  
phenylallyl)pyrrolidinium bromide (diastereomer 2);

(1\*, 3R)-1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-  
1-methylpyrrolidinium chloride (diastereomer 1);

(1\*,3S)-1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-  
methylpyrrolidinium chloride (diastereomer 1);

(1\*,3S)-1-[3-(4-Fluorophenoxy)propyl]-3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-  
methylpyrrolidinium chloride (diastereomer 2);

(1\*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-  
phenylpropyl)pyrrolidinium bromide (diastereomer 1);

(1\*, 3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-methyl-1-(3-  
phenylpropyl)pyrrolidinium bromide (diastereomer 2);

(1\*,3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-  
phenoxypropyl)pyrrolidinium bromide (diastereomer 1);

(1\*,3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-(3-  
phenoxypropyl)pyrrolidinium bromide (diastereomer 2);

(1\*, 3R)-1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-  
ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 1);


(1\*, 3R)-1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-  
ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 2);

(1\*, 3S)-1-Methyl-1-(3-o-tolyloxypropyl)-3-  
[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 1);

(1\*, 3S)-1-Methyl-1-(3-o-tolyloxypropyl)-3-  
[(9H-xanthen-9-ylcarbonyl)oxy]pyrrolidinium bromide (diastereomer 2);


(1\*, 3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride (diastereomer 1);  
 (1\*, 3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methylpyrrolidinium chloride (diastereomer 2);  
 (1\*, 3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide (diastereomer 1); and  
 (1\*, 3R)-3-[(2R)-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy]-1-methyl-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]pyrrolidinium bromide (diastereomer 2).

21. (Currently amended) A process for producing a compound of formula (I), as defined in any one of the preceding claims claimed in claim 1, which process ~~comprises~~ comprising reacting an alkylating agent of formula R4-W with an intermediate of formula (II):




wherein m, n, A, B, D, R1, R2, R3 and R4 are as defined in claim 1 and W is any suitable a leaving group.

22. (Currently amended) A process according to claim 21, wherein the compound of formula (II) is obtained by reaction of a compound of formula (V)



(V)

wherein ~~D is as defined in claim 1 and~~ L is a leaving group,  
with a compound of formula (VI)




(VI)


wherein ~~m, n, A, B, D, R1, R2 and R3 are as defined in claim 1.~~

23. (Currently amended) A compound of formula (II), ~~which is one of~~ chosen from:  
 2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(2-phenoxyethyl)pyrrolidin-3-yl ester;  
 2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(3-phenoxypropyl)pyrrolidin-3-yl ester;  
 2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-(3-thien-2-ylpropyl)pyrrolidin-3-yl ester; and  
 2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-phenethylpyrrolidin-3-yl ester.
24. (Currently amended) A compound of formula (VI), ~~which is one of~~ chosen from:  
 (3R)-1-(3-phenoxypropyl)pyrrolidin-3-ol and  
 (3R)-1-(3-thien-2-ylpropyl)pyrrolidin-3-ol.

25. (Currently amended) A process for producing a compound as claimed in claim 1, comprising of formula (I), as defined in any one of the preceding claims, which process comprises  
reacting an alkylating agent of formula (IV)



wherein ~~m, n, A, B, D, R1, R2 and R3 is as defined in claim 1 and W represents any suitable~~ leaving group,  
with an intermediate of formula (III)–



wherein ~~R4 and D are as defined in claim 1.~~

26. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 20~~as claimed in claim 1 in admixture with ~~a~~  
and at least one pharmaceutically acceptable carrier or diluent.

Claims 27-29 (Cancelled)

30. (Currently amended) A method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of M3 muscarinic

receptors, which ~~comprises~~comprising administering to said subject an effective amount of a compound as claimed in claim 1~~defined in any one of claims 1 to 20~~.

31. (Original) A method according to claim 30 wherein the pathological condition is a respiratory, urological or gastrointestinal disease or disorder.
32. (Currently amended) A ~~combination product~~composition comprising  
(i) a compound as claimed in claim 1~~according to any one of claims 1 to 20~~; and  
(ii) ~~another a~~ compound effective in the ~~treament~~treatment of a respiratory, urological or gastrointestinal disease or disorder  
~~for simultaneous, separate or sequential use.~~
33. (Currently amended) A composition~~combination product~~ according to claim 32 comprising  
(i) a compound as claimed in claim 1~~according to any one of claims 1 to 20~~; and  
(ii) ~~a~~at least one compound chosen from: a  $\beta$ 2 agonist, steroid, antiallergic drug, phosphodiesterase IV inhibitor and/or a leukotriene D4 (LTD4) antagonist  
~~for simultaneous, separate or sequential use in the treatment of a respiratory disease.~~
34. (New) A pharmaceutical composition according to claim 26, wherein the composition is an admixture.